GleamWall
中文EN

DBVT DBV Technologies S.A.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1613780 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-31.5%
TTM net income YoY-65.6%
TTM EPS YoY42.3%
Revenue 3-yr CAGR-11.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,418.8%
Net margin-5,392.2%
FCF margin-4,986.9%
EBITDA margin—

Returns

ROE-205.8%
ROA-127.2%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets31.0%
Debt / equity0.00x
Current ratio3.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.91x
Accruals ratio-11.6%
Payout ratio—
Capex / revenue87.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$5.64M$4.15M$15.73M$4.84M$5.71M
R&D expense$116.68M$89.34M$60.22M$75.54M$70.34M
SG&A expense$32.79M$28.74M$29.50M$24.32M$30.52M
Operating income-$147.06M-$116.59M-$76.43M-$96.63M-$98.61M
Pretax income-$146.46M-$113.86M-$72.72M-$96.20M-$98.19M
Income tax$491,000$55,000$7,000$70,000-$381,000
Net income-$146.95M-$113.92M$72.71M$96.27M-$97.81M
EBITDA-$144.07M-$113.87M-$72.87M-$93.93M-$94.21M
EPS (basic)-1.05-1.17-0.76-1.24-1.78
EPS (diluted)-1.05-1.17-0.76-1.24-1.78
Weighted avg. shares (diluted)139.57M97.00M95.12M77.38M54.92M
Balance sheet
Cash & equivalents$194.20M$32.50M$141.37M$209.19M$77.30M
Receivables——$0$0$0
Current assets$212.90M$44.39M$158.91M$223.07M$114.39M
PP&E, net$10.40M$11.31M$12.62M$15.10M$18.15M
Intangibles$0$40,000$58,000$10,000$22,000
Total assets$233.70M$65.66M$182.99M$246.52M$146.72M
Current liabilities$58.00M$31.14M$37.34M$29.52M$31.40M
Long-term debt$0———$510,000
Total debt$0———$510,000
Total liabilities$64.90M$38.27M$42.80M$52.06M$47.45M
Shareholders' equity$168.80M$27.40M$140.19M$194.45M$99.27M
Net debt-$194.20M———-$76.79M
Shares outstanding—102.85M———
Cash flow statement
Operating cash flow-$121.18M-$104.47M-$79.65M-$55.67M-$108.24M
Capital expenditure$532,000$2.34M$677,000$754,000$910,000
Free cash flow-$121.71M-$106.81M-$80.33M-$56.42M-$109.15M
Investing cash flow-$1.37M-$757,000-$808,000-$100,000-$433,000
Financing cash flow$276.18M$587,000$6.77M$194.12M$274,000
Depreciation & amortization$2.99M$2.72M$3.57M$2.70M$4.40M
Stock-based compensation$5.39M$4.62M$6.02M$5.03M$3.12M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.